Evidence map›Paper›PMID 18073397›Full record

ReviewProceedings of the American Thoracic Society2007

Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Fernando J Martinez

Abstract readReview
In one paragraph

Review in Proceedings of the American Thoracic Society, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Up-regulation of MUC18 in airway epithelial cells by IL-13: implications in bacterial adherence.American journal of respiratory cell and molecular biology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Fernando J MartinezDivision of Pulmonary and Critical Care Medicine, University of Michigan Health System, 1500 East Medical Center Drive, SPC 5360, Ann Arbor, MI 48109-5360, USA. fmartine@umich.edu

Funding

SCOR IN THE PATHOBIOLOGY OF FIBROTIC LUNG DISEASEP50HL056402 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TOEWS, GALEN B · 1997 to 2006
$13.3M
Novel Therapeutic Approaches in IPFU10HL080371 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARTINEZ, FERNANDO J · 2005 to 2009
$1.4M
IL-13 Fusion Cytotoxin as a Targeted Therapeutic for IIPR01HL073728 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOGABOAM, CORY M. · 2003 to 2006
$1.3M
PREDICTING RESPONSE TO THERAPY IN IDIOPATHIC PULMONARY FK24HL004212 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARTINEZ, FERNANDO J · 2000 to 2009
$1.2M
Prognostication In Idiopathic Interstitial PneumoniaK23HL068713 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FLAHERTY, KEVIN R · 2002 to 2006
$667k
NHLBI NIH HHS 1 K23 HL68713NHLBI NIH HHS 2K24HL04212NHLBI NIH HHS 5 P50 HL56402NHLBI NIH HHS K24 HL004212NHLBI NIH HHS N01-HR-46162NHLBI NIH HHS P50 HL056402NHLBI NIH HHS R01 HL073728NHLBI NIH HHS U10 HL080371
6 · The paper itself

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (COPD) are important events in the natural history of this chronic lung disorder. These events can be caused by a large number of infectious and noninfectious agents and are associated with an increased local and systemic inflammatory response. Their frequency and severity have been linked to progressive deterioration in lung function and health status. Infectious pathogens ranging from viral to atypical and typical bacteria have been implicated in the majority of episodes. Most therapeutic regimens to date have emphasized broad, nonspecific approaches to bronchoconstriction and pulmonary inflammation. Increasingly, therapy that targets specific etiologic pathogens has been advocated. These include clinical and laboratory-based methods to identify bacterial infections. Further additional investigation has suggested specific pathogens within this broad class. As specific antiviral therapies become available, better diagnostic approaches to identify specific pathogens will be required. Furthermore, prophylactic therapy for at-risk individuals during high-risk times may become a standard therapeutic approach. As such, the future will likely include aggressive diagnostic algorithms based on the combination of clinical syndromes and rapid laboratory modalities to identify specific causative bacteria or viruses.

Indexed as

Anti-Bacterial AgentsAntiviral AgentsDNA, ViralHumansPulmonary Disease, Chronic ObstructiveReverse Transcriptase Polymerase Chain ReactionSputumAnti-Bacterial AgentsAntiviral AgentsDNA, Viral

Identifiers

PMID18073397
PMCPMC2647652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.